REGN regeneron.com: קפיטליזציה חשבונאית

This chart of Regeneron Pharmaceuticals (REGN) price action is based on biopharmaceutical scalability, where the high margins of blockbuster drugs offset biotechnology costs, and the metric stands at 31.25. Growth is supported by plant modernization and the implementation of advanced bioreactors to expand antibody production. The company's success in cardiovascular medicine is driven by strategic alliances with global leaders for the joint study of immunology and genetics.

The successful rollout of Eylea HD and advancements in oncology are strengthening the financial foundation of Regeneron Pharmaceuticals (REGN). By analyzing the company's book capitalization, an investor can determine the actual value of net assets minus all liabilities. This metric reflects the residual capital available to shareholders in the event of business liquidation. Comparing this value to the market price allows for the identification of overvalued quotes. The steady growth of this indicator confirms the resilience of the model, even under pressure from biosimilars.